The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, P. R. China.
The Liver Center of Fujian Province, Fujian Medical University, Fuzhou, 350025, P. R. China.
ACS Synth Biol. 2022 Jan 21;11(1):1-15. doi: 10.1021/acssynbio.1c00256. Epub 2022 Jan 10.
Synthetic biology is a novel interdisciplinary research area following engineering principles to redesign and construct biological systems for useful purposes. As one of the most notable clinically relevant application of synthetic biology, chimeric antigen receptor (CAR) T cells have demonstrated tremendous success for the treatment of advanced hematological malignancies in recent years. However, various unsolved obstacles limit the widespread application of CAR T cell therapies, including treatment-associated toxicities, antigen heterogeneity, antigen escape, poor CAR T cell persistence and expansion, and particularly inefficient homing, infiltrating into, and surviving within solid tumors. Accordingly, to improve therapeutic efficacy and minimize side effects, innovative CAR design becomes urgently necessary, and researchers are developing numerous methods to overcome the limitations. Here we summarize currently available bioengineering strategies and discuss the future development from a viewpoint of synthetic biology.
合成生物学是一个新兴的跨学科研究领域，它遵循工程学原理，对生物系统进行重新设计和构建，以实现有用的目的。作为合成生物学最显著的临床相关应用之一，嵌合抗原受体（CAR）T 细胞近年来在治疗晚期血液恶性肿瘤方面取得了巨大成功。然而，各种未解决的障碍限制了 CAR T 细胞疗法的广泛应用，包括治疗相关毒性、抗原异质性、抗原逃逸、CAR T 细胞持久性和扩增不良，以及特别低效的归巢、浸润和在实体瘤中存活。因此，为了提高治疗效果并最小化副作用，创新的 CAR 设计变得非常必要，研究人员正在开发许多方法来克服这些限制。在这里，我们总结了目前可用的生物工程策略，并从合成生物学的角度讨论了未来的发展。
Zotero 插件